Document is current
Any future updates will be listed below
-
Authors
Fukuba, Nobuhiko https://orcid.org/0000-0003-3559-9490
Moriyama, Ichiro https://orcid.org/0000-0003-4753-5857
Onoe, Masaki https://orcid.org/0009-0001-8933-0895
Kodama, Yasuhide https://orcid.org/0009-0004-1343-792X
Kotani, Satoshi https://orcid.org/0000-0002-8916-8904
Oka, Akihiko https://orcid.org/0000-0001-6451-8413
Oshima, Naoki https://orcid.org/0000-0002-0861-9970
Kawashima, Kousaku https://orcid.org/0000-0002-5815-0066
Ishimura, Norihisa https://orcid.org/0000-0001-8039-3155
Ishihara, Shunji https://orcid.org/0000-0002-8228-1912
- License Information
-
More Information
Article History
Received: 8 June 2025
Revised: 26 July 2025
Accepted: 18 September 2025
First Online: 24 October 2025
Declarations
:
: This study was approved by the Medical Research Ethics Committee, Shimane University Faculty of Medicine (CRB6180008) on February 5, 2019. The approved study protocol is entitled “Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer: Phase Ib/II study (PC(UR-M) GEM/nab-PTX + MK615)” .
: The authors affirm that human research participants provided informed consent for publication.
: The authors have no conflicts of interest to declare.
